×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ALMS – alumis inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ALMS
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/6
05:38 pm
alms
Raymond James and Guggenheim Stay Bullish on Alumis (ALMS) After Trial Results [Yahoo! Finance]
Medium
Report
Raymond James and Guggenheim Stay Bullish on Alumis (ALMS) After Trial Results [Yahoo! Finance]
3/30
10:20 am
alms
Alumis (ALMS) had its price target raised by Oppenheimer Holdings, Inc. from $50.00 to $55.00. They now have an "outperform" rating on the stock.
High
Report
Alumis (ALMS) had its price target raised by Oppenheimer Holdings, Inc. from $50.00 to $55.00. They now have an "outperform" rating on the stock.
3/30
08:13 am
alms
Alumis (ALMS) had its "buy" rating reaffirmed by Chardan Capital. They now have a $38.00 price target on the stock.
High
Report
Alumis (ALMS) had its "buy" rating reaffirmed by Chardan Capital. They now have a $38.00 price target on the stock.
3/30
08:02 am
alms
Alumis (ALMS) had its price target lowered by HC Wainwright from $40.00 to $25.00. They now have a "buy" rating on the stock.
High
Report
Alumis (ALMS) had its price target lowered by HC Wainwright from $40.00 to $25.00. They now have a "buy" rating on the stock.
3/29
09:19 pm
alms
Alumis Spotlights Phase III Psoriasis Data for Envudeucitinib, Teases NDA and Lupus Readout [Yahoo! Finance]
High
Report
Alumis Spotlights Phase III Psoriasis Data for Envudeucitinib, Teases NDA and Lupus Readout [Yahoo! Finance]
3/28
01:38 pm
alms
Alumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis [Yahoo! Finance]
High
Report
Alumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis [Yahoo! Finance]
3/28
01:30 pm
alms
Alumis’ Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis
High
Report
Alumis’ Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis
3/20
09:24 am
alms
Alumis (ALMS) had its price target raised by Morgan Stanley from $33.00 to $38.00. They now have an "overweight" rating on the stock.
Medium
Report
Alumis (ALMS) had its price target raised by Morgan Stanley from $33.00 to $38.00. They now have an "overweight" rating on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/7
04:27 pm
alms
Form SCHEDULE 13G ALUMIS INC. Filed by: Deep Track Capital, LP
Low
Report
Form SCHEDULE 13G ALUMIS INC. Filed by: Deep Track Capital, LP
4/3
03:56 pm
alms
Form 4 ALUMIS INC. For: Apr 01 Filed by: Foresite Labs, LLC
Medium
Report
Form 4 ALUMIS INC. For: Apr 01 Filed by: Foresite Labs, LLC
4/3
03:55 pm
alms
Form 4 ALUMIS INC. For: Apr 01 Filed by: Foresite Labs Management I, LLC
Medium
Report
Form 4 ALUMIS INC. For: Apr 01 Filed by: Foresite Labs Management I, LLC
4/3
03:54 pm
alms
Form 4 ALUMIS INC. For: Apr 01 Filed by: Tananbaum James B.
Medium
Report
Form 4 ALUMIS INC. For: Apr 01 Filed by: Tananbaum James B.
4/3
03:51 pm
alms
Form SCHEDULE 13D/A ALUMIS INC. Filed by: Foresite Capital Fund VI LP
Medium
Report
Form SCHEDULE 13D/A ALUMIS INC. Filed by: Foresite Capital Fund VI LP
3/30
06:08 am
alms
Form 8-K ALUMIS INC. For: Mar 28
High
Report
Form 8-K ALUMIS INC. For: Mar 28
3/19
04:23 pm
alms
Form 10-K ALUMIS INC. For: Dec 31
Low
Report
Form 10-K ALUMIS INC. For: Dec 31
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: